Mats Eriksson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2024;31(15):1792-1803
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study
Ray KK; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrieres J; Laufs U; Mostaza JM; Nanchen D; Bardet A; Lamparter M; Chhabra R; Soronen J; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
Article: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):261
Prevalence of atherosclerosis in individuals with prediabetes and diabetes compared to normoglycaemic individuals-a Swedish population-based study
Ostgren CJ; Otten J; Festin K; Angeras O; Bergstrom G; Cederlund K; Engstrom G; Eriksson MJ; Eriksson M; Fall T; Gummesson A; Hagstrom E; Hellman U; James SK; Jernberg T; Kihlberg J; Kylhammar D; Markstad H; Nilsson P; Persson A; Persson M; Pirazzi C; Renklint R; Rosengren A; Soderberg S; Sundstrom J
Article: LANCET REGIONAL HEALTH-EUROPE. 2023;29:100624
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study
Ray KK; Haq I; Bilitou A; Manu MC; Burden A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrieres J; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(2):296-307
Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice
Pramfalk C; Ahmed O; Pedrelli M; Minniti ME; Luquet S; Denis RG; Olin M; Hardfeldt J; Vedin L-L; Steffensen KR; Ryden M; Hodson L; Eriksson M; Parini P
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;28(18):2038-2047
Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up
Littmann K; Hagstrom E; Habel H; Bottai M; Eriksson M; Parini P; Brinck J
Article: ATHEROSCLEROSIS PLUS. 2021;43:24-30
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe-Methodology and rationale for the multinational observational SANTORINI study
Ray KK; Haq I; Bilitou A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrieres J; Hildebrandt P; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
Article: JOURNAL OF INTERNAL MEDICINE. 2021;290(2):404-415
Founder effects facilitate the use of a genotyping-based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia
Benedek P; Jiao H; Duvefelt K; Skoog T; Linde M; Kiviluoma P; Kere J; Eriksson M; Angelin B
Article: DIABETES CARE. 2020;43(8):1851-1858
The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes
Littmann K; Wodaje T; Alvarsson M; Bottai M; Eriksson M; Parini P; Brinck J
Article: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS. 2020;1865(6):158659
Generation of new hepatocyte-like in vitro models better resembling human lipid metabolism
Pramfalk C; Jakobsson T; Verzijl CRC; Minniti ME; Obensa C; Ripamonti F; Olin M; Pedrelli M; Eriksson M; Parini P
Article: EUROPEAN HEART JOURNAL: CASE REPORTS. 2020;4(1):1-6
Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report
Littmann K; Szummer K; Hagstrom H; Dolapcsiev K; Brinck J; Eriksson M
Article: MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2020;499:110604
Diiodothyronines regulate metabolic homeostasis in primary human hepatocytes by modulating mTORC1 and mTORC2 activity
Gnocchi D; Ellis ECS; Johansson H; Eriksson M; Bruscalupi G; Steffensen KR; Parini P
Article: DIGESTIVE AND LIVER DISEASE. 2019;51(7):1016-1022
Genetic depletion of Soat2 diminishes hepatic steatosis via genes regulating de novo lipogenesis and by GLUT2 protein in female mice
Ahmed O; Pramfalk C; Pedrelli M; Olin M; Steffensen KR; Eriksson M; Parini P
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2019;5(3):225-232
Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data
Lindh M; Banefelt J; Fox KM; Hallberg S; Tai M-H; Eriksson M; Villa G; Svensson MK; Qian Y
Article: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2018;7(24):e009876
Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
Ahmed O; Littmann K; Gustafsson U; Pramfalk C; Oorni K; Larsson L; Minniti ME; Sahlin S; Camejo G; Parini P; Eriksson M
Article: JOURNAL OF INTERNAL MEDICINE. 2018;284(6):674-684
Genetic testing for familial hypercholesterolemia among survivors of acute coronary syndrome
Benedek P; Eriksson M; Duvefelt K; Freyschuss A; Frick M; Lundman P; Nylund L; Szummer K
Article: ATHEROSCLEROSIS. 2018;275:246-255
Overexpression of transforming growth factor β induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption
Parini P; Melhuish TA; Wotton D; Larsson L; Ahmed O; Eriksson M; Pramfalk C
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2017;377(9):839-848
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE; Ørsted DD; Brown-Frandsen K; Marso SP; Poulter NR; Rasmussen S; Tornøe K; Zinman B; Buse JB; LEADER Steering Committee and Investigators
Article: JOURNAL OF INTERNAL MEDICINE. 2017;281(6):575-585
Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III
Laskar MG; Eriksson M; Rudling M; Angelin B
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2017;47(1):38-43
High-density lipoprotein-associated sphingosine-1-phosphate activity in heterozygous familial hypercholesterolaemia
Frias MA; Thomas A; Brulhart-Meynet M-C; Kovamees O; Pernow J; Eriksson M; Angelin B; James RW; Brinck JW
Article: JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2016;30(8):1631-1639
LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population
Satman I; Rea RR; Eriksson M; Mosenzon O; Pratley R; Baeres FM; Orsted DD; Mann JF
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2016;72(10):1171-1176
Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences
Skilving I; Eriksson M; Rane A; Ovesjo M-L
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2016;375(4):311-322
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JFE; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; LEADER Steering Committee; LEADER Trial Investigators
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2016;118(6):499-502
Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations
Bjorkhem-Bergman L; Nylen H; Eriksson M; Parini P; Diczfalusy U
Article: JOURNAL OF INTERNAL MEDICINE. 2016;279(5):477-484
Arginase inhibition improves endothelial function in patients with familial hypercholesterolaemia irrespective of their cholesterol levels
Kovamees O; Shemyakin A; Eriksson M; Angelin B; Pernow J
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2016;36(5):817-824
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection
Brinck JW; Thomas A; Lauer E; Jornayvaz FR; Brulhart-Meynet M-C; Prost J-C; Pataky Z; Lofgren P; Hoffstedt J; Eriksson M; Pramfalk C; Morel S; Kwak BR; van Eck M; James RW; Frias MA
Article: CARDIOVASCULAR DIABETOLOGY. 2016;15:29
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
Masmiquel L; Leiter LA; Vidal J; Bain S; Petrie J; Franek E; Raz I; Comlekci A; Jacob S; van Gaal L; Baeres FMM; Marso SP; Eriksson M
Article: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 2016;1861(1):51-59
Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism
Pramfalk C; Larsson L; Hardfeldt J; Eriksson M; Parini P
Article: JOURNAL OF INTERNAL MEDICINE. 2015;277(3):331-342
Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome
Angelin B; Kristensen JD; Eriksson M; Carlsson B; Klein I; Olsson AG; Ridgway EC; Ladenson PW
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2014;63(13):1278-1288
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal FJ; Giugliano RP; Sabatine MS; Koren MJ; Langslet G; Bays H; Blom D; Eriksson M; Dent R; Wasserman SM; Huang F; Xue A; Albizem M; Scott R; Stein EA
Article: JOURNAL OF LIPID RESEARCH. 2014;55(4):709-717
TG-interacting factor 1 acts as a transcriptional repressor of sterol O-acyltransferase 2
Pramfalk C; Melhuish TA; Wotton D; Jiang Z-Y; Eriksson M; Parini P
Article: PLOS ONE. 2014;9(4):e93552
Hepatic ACAT2 Knock Down Increases ABCA1 and Modifies HDL Metabolism in Mice
Pedrelli M; Davoodpour P; Degirolamo C; Gomaraschi M; Graham M; Ossoli A; Larsson L; Calabresi L; Gustafsson J-A; Steffensen KR; Eriksson M; Parini P
Article: DRUG METABOLISM AND DISPOSITION. 2013;41(9):1610-1615
Atorvastatin Treatment Induces Uptake and Efflux Transporters in Human Liver
Bjorkhem-Bergman L; Bergstrom H; Johansson M; Parini P; Eriksson M; Rane A; Ekstrom L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2012;417(3):1046-1051
Statins inhibit expression of Thioredoxin reductase 1 in rat and human liver and reduce tumour development
Skogastierna C; Johansson M; Parini P; Eriksson M; Eriksson LC; Ekstrom L; Bjorkhem-Bergman L
Article: NATURE. 2011;478(7367):110-113
Dynamics of human adipose lipid turnover in health and metabolic disease
Arner P; Bernard S; Salehpour M; Possnert G; Liebl J; Steier P; Buchholz BA; Eriksson M; Arner E; Hauner H; Skurk T; Ryden M; Frayn KN; Spalding KL
Article: ADVANCES IN THERAPY. 2011;28(9):811-823
Comparative Efficacy of Pitavastatin and Simvastatin in High-Risk Patients: a Randomized Controlled Trial
Eriksson M; Budinski D; Hounslow N
Article: ADVANCES IN THERAPY. 2011;28(9):799-810
Long-Term Efficacy of Pitavastatin Versus Simvastatin
Eriksson M; Budinski D; Hounslow N
Article: JOURNAL OF INTERNAL MEDICINE. 2011;269(3):333-339
Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism
Pramfalk C; Parini P; Gustafsson U; Sahlin S; Eriksson M
Article: JOURNAL OF CARDIOVASCULAR RISK. 2011;18(1):97-105
Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register
Eriksson M; Zethelius B; Eeg-Olofsson K; Nilsson PM; Gudbjornsdottir S; Cederholm J; Eliasson B
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2011;71(1):63-67
L-thyroxine treatment in primary hypothyroidism does not increase the content of free triiodothyronine in cerebrospinal fluid: A pilot study
Sjoberg S; Eriksson M; Werner S; Bjellerup P; Nordin C
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2010;30(12):2666-2672
Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
Persson L; Cao G; Stahle L; Sjoberg BG; Troutt JS; Konrad RJ; Galman C; Wallen H; Eriksson M; Hafstrom I; Lind S; Dahlin M; Amark P; Angelin B; Rudling M
Article: JOURNAL OF LIPID RESEARCH. 2010;51(6):1354-1362
HNF1α and SREBP2 are important regulators of NPC1L1 in human liver
Pramfalk C; Jiang Z-Y; Cai Q; Hu H; Zhang S-D; Han T-Q; Eriksson M; Parini P
Article: ATHEROSCLEROSIS. 2009;207(1):266-271
ACAT2 and human hepatic cholesterol metabolism: Identification of important gender-related differences in normolipidemic, non-obese Chinese patients
Parini P; Jiang Z-Y; Einarsson C; Eggertsen G; Zhang S-D; Rudel LL; Han T-Q; Eriksson M
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2009;29(8):1235-1241
Control of ACAT2 Liver Expression by HNF4α Lesson From MODY1 Patients
Pramfalk C; Karlsson E; Groop L; Rudel LL; Angelin B; Eriksson M; Parini P
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2009;301(11):1131-1139
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
Meuwese MC; de Groot E; Duivenvoorden R; Trip MD; Ose L; Maritz FJ; Basart DCG; Kastelein JJP; Habib R; Davidson MH; Zwinderman AH; Schwocho LR; Stein EA; CAPTIVATE Investigators
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2009;379(1):49-54
Increased NPC1L1 and ACAT2 expression in the jejunal mucosa from Chinese gallstone patients
Jiang Z-Y; Jiang C-Y; Wang L; Wang J-C; Zhang S-D; Einarsson C; Eriksson M; Han T-Q; Parini P; Eggertsen G
Article: CELL METABOLISM. 2008;8(2):169-174
The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man
Gaelman C; Lundasen T; Kharitonenkov A; Bina HA; Eriksson M; Hafstroem I; Dahlin M; Amark P; Angelin B; Rudling M
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2008;28(6):1200-1206
Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2
Parini P; Gustafsson U; Davis MA; Larsson L; Einarsson C; Wilson M; Rudling M; Tomoda H; Omura S; Sahlin S; Angelin B; Rudel LL; Eriksson M
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2007;364(2):402-409
Cholesterol regulates ACAT2 gene expression and enzyme activity in human hepatoma cells
Pramfalk C; Angelin B; Eriksson M; Parini P
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2007;357(21):2109-2122
Effects of torcetrapib in patients at high risk for coronary events
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJP; Komajda M; Lopez-Sendon J; Mosca L; Tardif J-C; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B
Article: JOURNAL OF LIPID RESEARCH. 2005;46(9):1868-1876
Control of ACAT2 liver expression by HNF1
Pramfalk C; Davis MA; Eriksson M; Rudel LL; Parini P
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2005;65(5):365-375
Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid
Babiker A; Dzeletovic S; Wiklund B; Pettersson N; Salonen J; Nyyssönen K; Eriksson M; Diczfalusy U; Björkhem I
Article: JOURNAL OF INTERNAL MEDICINE. 2004;256(5):406-412
Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment
Lind S; Olsson AG; Eriksson M; Rudling M; Eggertsen G; Angelin B
Article: CIRCULATION. 2004;110(14):2017-2023
ACAT2 is localized to Hepatocytes and is the major cholesterol-esterifying enzyme in human liver
Parini P; Davis M; Lada AT; Erickson SK; Wright TL; Gustafsson U; Sahlin S; Einarsson C; Eriksson M; Angelin B; Tomoda H; Omura S; Willingham MC; Rudel LL
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2004;24(2):349-356
Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans
Lind S; Rudling M; Ericsson S; Olivecrona H; Eriksson M; Borgström B; Eggertsen G; Berglund L; Angelin B
Article: APPETITE. 2003;41(2):213-214
Changes in cerebrospinal fluid signalling substances and appetite scores following 48 h fast in healthy volunteers
Arner P; Sjöberg S; Nordin C; Eriksson M
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13(5):333-335
CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype
Nordin C; Dahl ML; Eklundh T; Eriksson M; Sjöberg S
Article: THERAPEUTIC APHERESIS AND DIALYSIS. 2003;7(1):115-118
Micro- and macrocirculatory effects of apheresis in patients with familial hyperlipidemia
Lu Q; Eriksson M; Jogestrand T; Henriksson T; Freyschuss A
Article: CLINICAL THERAPEUTICS. 2003;25(1):119-138
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets:: The treat-to-target (3T) study
Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O
Article: ATHEROSCLEROSIS SUPPLEMENTS. 2002;3(4):23-30
Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL
Angelin B; Parini P; Eriksson M
Article: ATHEROSCLEROSIS. 2002;163(2):399-407
Genetic characterization of Swedish patients with familial hypercholesterolemia: a heterogeneous pattern of mutations in the LDL receptor gene
Lind S; Rystedt E; Eriksson M; Wiklund O; Angelin B; Eggertsen G
Article: JOURNAL OF INTERNAL MEDICINE. 2002;251(4):331-337
Quality of life in patients with familial hypercholesterolaemia.
Hollman G; Gullberg M; Ek A-C; Eriksson M; Olsson AG
Article: NEUROPSYCHOBIOLOGY. 2001;43(2):70-74
Depressive symptoms in hypothyroid disorder with some observations on biochemical correlates
Gunnarsson T; Sjöberg S; Eriksson M; Nordin C
Article: NEUROPSYCHOBIOLOGY. 2001;43(1):19-22
CSF collection time at lumbar puncture is influenced by plasma cholesterol and triglycerides
Nordin C; Eklundh T; Eriksson M; Sjöberg S
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2000;30(10):866-870
LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion
Stenvinkel P; Alvestrand A; Angelin B; Eriksson M
Article: CONTROL AND CYBERNETICS. 2000;29(1):405-425
Kinetic analysis of LDL apoB transport and metabolism in non-steady states
Werynski A; Nahorski Z; Angelin B; Berglund L; Eriksson M
Article: CIRCULATION. 1999;100(6):594-598
Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I - Potential reverse cholesterol transport in humans
Eriksson M; Carlson LA; Miettinen TA; Angelin B
Article: JOURNAL OF NEURAL TRANSMISSION. 1999;106(3-4):275-282
Cholecystokinin peptides in cerebrospinal fluid:: a study in healthy male subjects lumbar-punctured without preceding strict bed-rest
Gunnarsson T; Eklundh T; Eriksson M; Sjöberg S; Nordin C
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1999;29(4):291-300
Evidence of circadian rhythm in low-density lipoprotein apoB catabolism and its impact on the estimation of kinetic parameters
Werynski A; Nahorski Z; Berglund L; Ericsson S; Angelin B; Eriksson M
Article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 1999;14(2):113-117
Cholecystokinin peptides in cerebrospinal fluid:: a pilot study in hypothyroid patients
Gunnarsson T; Sjöberg S; Eriksson M; Nordin C
Article: EUROPEAN JOURNAL OF ENDOCRINOLOGY. 1998;139(5):493-497
L-thyroxine treatment and neurotransmitter levels in the cerebrospinal fluid of hypothyroid patients:: a pilot study
Sjöberg S; Eriksson M; Nordin C
Article: LIPIDS. 1998;33(8):811-815
Analysis of ubiquinone and tocopherol levels in normal and hyperlipidemic human plasma
Zhang YY; Eriksson M; Dallner G; Appelkvist EL
Article: JOURNAL OF INTERNAL MEDICINE. 1998;244(1):19-25
Low frequency of the common Norwegian and Finnish LDL-receptor mutations in Swedish patients with familial hypercholesterolaemia
Lind S; Eriksson M; Rystedt E; Wiklund O; Angelin B; Eggertsen G
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1998;28(3):235-242
Gemfibrozil-induced decrease in serum ubiquinone and α- and γ-tocopherol levels in men with combined hyperlipidaemia
Åberg F; Appelkvist EL; Bröijersen A; Eriksson M; Angelin B; Hjemdahl P; Dallner G
Article: THROMBOSIS AND HAEMOSTASIS. 1998;79(2):268-275
Platelet activity in vivo in hyperlipoproteinemia -: Importance of combined hyperlipidemia
Bröijersén A; Hamsten A; Eriksson M; Angelin B; Hjemdahl P
Article: GUT. 1997;41(5):700-704
The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans
Hillebrant CG; Nyberg B; Einarsson K; Eriksson M
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 1997;17(10):2287-2292
Adipose tissue lipoprotein lipase and hormone-sensitive lipase - Contrasting findings in familial combined hyperlipidemia and insulin resistance syndrome
Reynisdottir S; Angelin B; Langin D; Lithell H; Eriksson M; Holm C; Arner P
Article: LANCET. 1997;350(9070):29-30
Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
Nordin C; Dahl ML; Eriksson M; Sjoberg S
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1997;27(2):169-177
Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome
Stenvinkel P; Berglund L; Ericsson S; Alvestrand A; Angelin B; Eriksson M
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 1997;17(2):273-278
No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia
Broijersen A; Eriksson M; Leijd B; Angelin P; Hjemdahl P
Article: REGULATORY PEPTIDES. 1997;68(1):57-61
Cholecystokinin peptides in cerebrospinal fluid: A study in healthy male subjects
Gunnarsson T; Eklundh T; Eriksson M; Qureshi GA; Sjoberg S; Nordin C
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1996;26(12):1160-1165
Changes in biliary lipid output after interruption of pravastatin treatment in humans
Hillebrant CG; Eriksson M; Nyberg B; Einarsson K
Article: BIOLOGICAL PSYCHIATRY. 1996;40(4):302-304
Cholesterol lowering and cerebrospinal fluid neurotransmitters: Increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin administration to healthy male volunteers
Eriksson M; Eklundh T; Sjoberg S; Angelin B; Nordin C
Article: THROMBOSIS AND HAEMOSTASIS. 1996;76(2):171-176
Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII
Broijersen A; Hamsten A; Silveira A; Fatah K; Goodall AH; Eriksson M; Angelin B; Hjemdahl P
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 1996;81(7):2633-2637
Hormonal regulation of serum lipoprotein (a) levels: Effects of parenteral administration of estrogen or testosterone in males
Berglund L; Carlstrom K; Stege R; Gottlieb C; Eriksson M; Angelin B; Henriksson P
Article: JOURNAL OF PSYCHIATRIC RESEARCH. 1996;30(3):201-208
Monoamine precursors, transmitters and metabolites in cerebrospinal fluid: A prospective study in healthy male subjects
Eklundh T; Eriksson M; Sjoberg S; Nordin C
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 1996;16(4):511-516
Gemfibrozil treatment of combined hyperlipoproteinemia - No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels
Broijersen A; Eriksson M; Wiman B; Angelin B; Hjemdahl P
Article: JOURNAL OF CLINICAL INVESTIGATION. 1995;95(5):2161-2169
IMPAIRED ACTIVATION OF ADIPOCYTE LIPOLYSIS IN FAMILIAL COMBINED HYPERLIPIDEMIA
REYNISDOTTIR S; ERIKSSON M; ANGELIN B; ARNER P
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 1995;15(1):121-127
GEMFIBROZIL ENHANCES PLATELET ACTIVITY IN PATIENTS WITH COMBINED HYPERLIPOPROTEINEMIA
BROIJERSEN A; ERIKSSON M; ANGELIN B; HJEMDAHL P
Visa fler

Alla övriga publikationer

Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2019;286(6):723-725
How to handle hypertriglyceridaemia in acute pancreatitis - Still a vote for conservatives?
Eriksson M; Angelin B
Meeting abstract: ATHEROSCLEROSIS. 2019;287:e111
LIPOPROTEIN (A) PLASMA LEVELS AND ASSOCIATION TO CARDIOVASCULAR DISEASE IN A STOCKHOLM COUNTY COHORT - A RETROSPECTIVE OBSERVATIONAL COHORT REGISTRY STUDY
Littmann K; Brinck J; Eriksson M; Parini P
Review: LAKARTIDNINGEN. 2019;116:FLMW
[Sweden introduces a new specific ICD-10 code for the disease familial hypercholesterolemia].
Brinck J; Hagström E; Benedek P; Hedelin R; Muhr T; Svennberg L; Reinhardt W; Eriksson M
Other: LAKARTIDNINGEN. 2018;115:E9YY
Tidig diagnos och behandling med gallsyra avgörande vid cerebrotendinös xantomatos.
Eggertsen G; Puschmann A; Hall S; Wärme A-K; Kvorning O; Olin M; Eriksson M; Björkhem I
Meeting abstract: ATHEROSCLEROSIS. 2018;275:e234
SIMVASTATIN AND EZETIMIBE REDUCE PLASMA LIPOPROTEIN BINDING TO HUMAN ARTERIAL PROTEOGLYCANS IN GALLSTONE DISEASED PATIENTS
Littmann K; Ahmed O; Gustafsson U; Pramfalk C; Oorni K; Larsson L; Sahlin S; Camejo G; Parini P; Eriksson M
Meeting abstract: ATHEROSCLEROSIS. 2018;275:e33
WHY ARE HUMANS LDL-ANIMALS AND MICE ARE NOT? HEPATIC APOB MRNA EDITING AND PLASMA PLTP ACTIVITY ARE THE CAUSE, NOT CETP
Minniti ME; Pedrelli M; Vedin L-L; Delbes A-S; Oorni K; Wilson EM; Luquet S; Eriksson M; Parini P
Meeting abstract: ATHEROSCLEROSIS. 2018;275:e25
GENETIC DEPLETION OF THE SOAT2 GENE DIMINISHES DIET-INDUCED HEPATIC STEATOSIS AND IMPROVES GLUCOSE TOLERANCE IN MICE
Pramfalk C; Ahmed O; Larsson L; Hardfeldt J; Pedrelli M; Vedin L; Steffensen K; Tellez M; Delbes A; Denis R; Luquet S; Eriksson M; Parini P
Letter: JOURNAL OF INTERNAL MEDICINE. 2018;283(6):604-606
Unique case of cerebrotendinous xanthomatosis revisited: All the mutations responsible for this disease are present in the CYP27A1 gene
Jiao H; Olin M; Hansson M; Eggertsen G; Eriksson M; Angelin B; Bjorkhem I
Meeting abstract: ATHEROSCLEROSIS. 2017;263:e62
THE USE OF GENOTYPING AS A FIRST STEP IN MOLECULAR DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA
Benedek P; Angelin B; Duvefelt K; Hong J; Kere J; Rudling M; Eriksson M
Meeting abstract: ATHEROSCLEROSIS. 2016;252:E62
REMNANT CHOLESTEROL REDUCTION BY EZETIMIBE AND SIMVASTATIN DOES NOT AFFECT BILIARY LIPID CONCENTRATION IN GALLSTONE PATIENTS
Eriksson M; Ahmed O; Gustafsson U; Littman K; Sahlin S; Pramfalk C; Parini P
Meeting abstract: ATHEROSCLEROSIS. 2016;252:e240
WORKSHOP 2.2: ADIPOSE TISSUE - LIVER AXIS. SOAT2 DEPLETION IMPROVES INSULIN SENSITIVITY AND HEPATIC STEATOSIS
Parini P; Pramfalk C; Ahmed O; Larsson L; Karpe F; Neville M; Eriksson M
Published conference paper: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 2015;1851(1):9-12
Role of TG-interacting factor (Tgif) in lipid metabolism
Pramfalk C; Eriksson M; Parini P
Review: EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY. 2012;114(6):624-633
Cholesteryl esters and ACAT
Pramfalk C; Eriksson M; Parini P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2011;12(1):39
THE INHIBITION OF HEPATIC ACYL COENZYME A:CHOLESTEROL ACYLTRANSFERASE (ACAT) 2 POSITIVELY AFFECTS HDL METABOLISM AND FUNCTIONALITY IN MICE
Pedrelli M; Davoodpour P; Degirolamo C; Gomaraschi M; Larsson L; Rudel LL; Calabresi L; Gustafsson JA; Steffensen K; Eriksson M; Parini P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2011;12(1):34
TG INTERACTING FACTOR ACTS AS A TRANSCRIPTIONAL REPRESSOR OF ACAT2 IN HUMAN
Pramfalk C; Eriksson M; Parini P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2011;12(1):7
LIPID-LOWERING EFFECTS OF THE THYROID HORMONE ANALOGUE EPROTIROME REQUIRES FUNCTIONAL LDL RECEPTORS: STUDIES IN A HOMOZYGOUS FH PATIENT
Benedek P; Angelin B; Kristensen J; Rudling M; Eriksson M
Review: CURRENT OPINION IN LIPIDOLOGY. 2010;21(6):492-498
Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe
Thompson GR; Catapano A; Saheb S; Atassi-Dumont M; Barbir M; Eriksson M; Paulweber B; Sijbrands E; Stalenhoef AF; Parhofer KG
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2010;11(2):64
EFFECTS OF HIGH DOSE STATIN ON THE HUMAN HEPATIC EXPRESSION OF GENES INVOLVED IN CARBOHYDRATE AND TRIGLYCERIDE METABOLISM
Pramfalk C; Parini P; Gustafsson U; Sahlin S; Eriksson M
Published conference paper: CLINICAL THERAPEUTICS. 2010;32(4):615-625
Colesevelam Added to Combination Therapy With a Statin and Ezetimibe in Patients With Familial Hypercholesterolemia: A 12-Week, Multicenter, Randomized, Double-Blind, Controlled Trial
Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AFH; Imholz BPM; Durrington PN; Trip MD; Eriksson M; Visseren FLJ; Schaefer JR; Kastelein JJP
Letter: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2009;302(3):255
Carotid Atherosclerosis Progression and ACAT Inhibition
Parini P; Eriksson M; Rudel LL
Published conference paper: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2008;42(4):279-287
Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia
Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2008;9(1):212
LIPID LOWERING TREATMENT PATTERNS AND GOAL ATTAINMENT IN NORDIC PATIENTS WITH HYPERLIPIDEMIA
Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2008;9(1):33
CHOLESTEROL REGULATES ACAT2 GENE EXPRESSION AND ENZYME ACTIVITY IN HUMAN HEPATOMA CELLS
Pramfalk C; Angelin B; Eriksson M; Parini P
Corrigendum: NEW ENGLAND JOURNAL OF MEDICINE. 2008;358(18):1977
Simvastatin with or without ezetimibe in familial hypercholesterolemia (vol 358, pg 1431, 2008)
Kastelein JJP; Akdim F; Stroes ESG; Zwinderman AH; Bots ML; Stalenhoef AFH; Visseren FLJ; Sijbrands EJG; Trip MD; Stein EA; Gaudet D; Duivenvoorden R; Veltri EP; Marais AD; de Groot E
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2007;8(1):43
HNF4 alpha is essential for ACAT2 regulation in human: Lesson from the mody patients
Pramfalk C; Karlsson E; Eriksson M; Angelin B; Groop L; Rudel LL; Parini P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2007;8(1):21
Reduction of ACAT2 is an important effect of cholesterol synthesis inhibition in human livers
Parini P; Gustafsson U; Einarsson C; Shalin S; Rudling M; Angelin B; Rudel LL; Eriksson M
Review: LAKARTIDNINGEN. 2006;103(10):751-752
[The apoB/apoA-I ratio is better myocardial infarction marker than lipids].
Walldius G; Angelin B; Eriksson M
Letter: JOURNAL OF INTERNAL MEDICINE. 2005;257(3):313-314
Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine'
Eriksson M; Angelin B; Sjöberg S
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2003;4(2):233
New molecular effects of cholesterol synthesis inhibition on hepatic cholesterol metabolism in humans
Eriksson M; Davis MA; Gustafsson U; Willingham MC; Einarsson C; Angelin B; Sahlin S; Rudel LL; Parini P
Review: CURRENT OPINION IN LIPIDOLOGY. 1999;10(3):269-274
Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era?
Angelin B; Eriksson M; Rudling M
Review: LAKARTIDNINGEN. 1998;95(35):3670-3672
[Statins have other beneficial properties besides their cholesterol lowering effect].
Eriksson M
Meeting abstract: ATHEROSCLEROSIS. 1997;134(1-2):188
Platelet function in hypercholesterolemia - importance of combined hyperlipidemia
Broijersen A; Hamsten A; Eriksson M; Angelin B; Hjemdahl P
Visa fler

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI